|
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
|
Sep 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Blood consult: paroxysmal nocturnal hemoglobinuria and its complications.
|
Sep 2013
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
|
Sep 2013
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Epidemiology and risk factors for infections in myelodysplastic syndromes.
|
Sep 2013
|
Transpl Infect Dis
|
myelodysplastic syndromes (MDS)
|
|
Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes.
|
Sep 2013
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
|
Aug 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes.
|
Aug 2013
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
|
Costs and quality of life in patients with myelodysplastic syndromes.
|
Aug 2013
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
|
Aug 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.
|
Aug 2013
|
Blood
|
aplastic anemia
|
